INFINITY PHARMACEUTICALS, INC.

2023 Q3 Form 10-Q Financial Statement

#000111314823000009 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.75M $56.58M
YoY Change -68.63% -41.83%
Cash & Equivalents $17.70M $45.84M
Short-Term Investments $10.74M
Other Short-Term Assets $377.0K $3.035M
YoY Change -87.58% 1148.97%
Inventory
Prepaid Expenses $1.785M
Receivables
Other Receivables
Total Short-Term Assets $19.91M $59.61M
YoY Change -66.6% -40.2%
LONG-TERM ASSETS
Property, Plant & Equipment $589.0K $1.904M
YoY Change -69.07% 29.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $84.00K $343.0K
YoY Change -75.51% 736.59%
Total Long-Term Assets $1.324M $2.247M
YoY Change -41.08% -23.07%
TOTAL ASSETS
Total Short-Term Assets $19.91M $59.61M
Total Long-Term Assets $1.324M $2.247M
Total Assets $21.23M $61.86M
YoY Change -65.68% -39.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.502M $1.813M
YoY Change -17.15% 90.04%
Accrued Expenses $10.56M $12.53M
YoY Change -15.68% 30.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.06M $14.34M
YoY Change -15.87% 35.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $48.63M
YoY Change -100.0% 20769.1%
Total Long-Term Liabilities $0.00 $48.63M
YoY Change -100.0% 20769.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.06M $14.34M
Total Long-Term Liabilities $0.00 $48.63M
Total Liabilities $58.64M $62.96M
YoY Change -6.87% 3.12%
SHAREHOLDERS EQUITY
Retained Earnings -$877.0M
YoY Change
Common Stock $839.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$37.41M -$1.107M
YoY Change
Total Liabilities & Shareholders Equity $21.23M $61.86M
YoY Change -65.68% -39.71%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3495000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11986000 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001113148
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#RoyaltyMember
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#RoyaltyMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#RoyaltyMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#RoyaltyMember
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.infi.com/20230630#AccruedLiabilitiesAndOtherCurrentLiabilities
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.infi.com/20230630#AccruedLiabilitiesAndOtherCurrentLiabilities
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
INFINITY PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0655706
dei Entity Address Address Line1
EntityAddressAddressLine1
1100 Massachusetts Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Floor 4
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02138
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
453-1000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
INFI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
90761081 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17746000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38313000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2162000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1989000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
19908000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
40302000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
589000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
800000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
158000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
158000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
493000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
697000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
84000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
194000 usd
CY2023Q2 us-gaap Assets
Assets
21232000 usd
CY2022Q4 us-gaap Assets
Assets
42151000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1502000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4405000 usd
CY2023Q2 infi Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
10562000 usd
CY2022Q4 infi Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
9223000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12064000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13628000 usd
CY2023Q2 infi Liability For Sale Of Future Royalties Noncurrent
LiabilityForSaleOfFutureRoyaltiesNoncurrent
46574000 usd
CY2022Q4 infi Liability For Sale Of Future Royalties Noncurrent
LiabilityForSaleOfFutureRoyaltiesNoncurrent
47213000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
324000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
37000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
58638000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
61202000 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90761081 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90761081 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89411471 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89411471 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
90000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
89000 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
839457000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
836812000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-876953000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-855952000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37406000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-19051000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21232000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42151000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
583000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
686000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1314000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1338000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6597000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8795000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12450000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17785000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3754000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9698000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7171000 usd
CY2023Q2 us-gaap Royalty Expense
RoyaltyExpense
352000 usd
CY2022Q2 us-gaap Royalty Expense
RoyaltyExpense
414000 usd
us-gaap Royalty Expense
RoyaltyExpense
793000 usd
us-gaap Royalty Expense
RoyaltyExpense
807000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
10703000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12704000 usd
us-gaap Operating Expenses
OperatingExpenses
22941000 usd
us-gaap Operating Expenses
OperatingExpenses
25763000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10120000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12018000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-21627000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-24425000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
209000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
77000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
716000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
93000 usd
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
45000 usd
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
45000 usd
us-gaap Interest Expense Other
InterestExpenseOther
90000 usd
us-gaap Interest Expense Other
InterestExpenseOther
90000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
164000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
32000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
626000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9956000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21001000 usd
us-gaap Net Income Loss
NetIncomeLoss
-24422000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89885492 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89885492 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89161777 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89161777 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89650793 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89650793 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89158562 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89158562 shares
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9956000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11984000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21001000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24440000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21001000 usd
us-gaap Net Income Loss
NetIncomeLoss
-24422000 usd
us-gaap Depreciation
Depreciation
211000 usd
us-gaap Depreciation
Depreciation
241000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2630000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1682000 usd
infi Noncash Royalty Revenue
NoncashRoyaltyRevenue
695000 usd
infi Noncash Royalty Revenue
NoncashRoyaltyRevenue
708000 usd
infi Amortization Of Debt Issuance Costs And Liability For Sale Of Future Royalties Net
AmortizationOfDebtIssuanceCostsAndLiabilityForSaleOfFutureRoyaltiesNet
90000 usd
infi Amortization Of Debt Issuance Costs And Liability For Sale Of Future Royalties Net
AmortizationOfDebtIssuanceCostsAndLiabilityForSaleOfFutureRoyaltiesNet
90000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
220000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-66000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
63000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1624000 usd
infi Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-204000 usd
infi Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-177000 usd
infi Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-1455000 usd
infi Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
616000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-284000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-248000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20583000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24130000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
16019000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
5250000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10786000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
16000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
28000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20567000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34888000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38471000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80884000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17904000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45996000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17746000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45838000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
158000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
158000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17904000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45996000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-28322000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
856000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9956000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37406000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9982000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
815000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
80000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11986000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1107000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-19051000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2630000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21001000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37406000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21571000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1682000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
80000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000 usd
us-gaap Net Income Loss
NetIncomeLoss
-24422000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1107000 usd
CY2023Q2 infi Cash And Cash Equivalents And Available For Sale Securities Estimated Fair Value
CashAndCashEquivalentsAndAvailableForSaleSecuritiesEstimatedFairValue
17700000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-877000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20600000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
856000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
815000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2630000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1682000 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5100000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2776324 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.11
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.37
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17700000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38300000 usd
infi Unrealized Gain Loss On Cash And Cash Equivalents
UnrealizedGainLossOnCashAndCashEquivalents
0 usd
CY2022 infi Unrealized Gain Loss On Cash And Cash Equivalents
UnrealizedGainLossOnCashAndCashEquivalents
0 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17700000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38300000 usd
CY2023Q2 infi Target Net Asset Value
TargetNetAssetValue
1.00 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1785000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1429000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
377000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
560000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2162000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1989000 usd
CY2023Q2 infi Accrued Clinical Studies
AccruedClinicalStudies
4714000 usd
CY2022Q4 infi Accrued Clinical Studies
AccruedClinicalStudies
4290000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1224000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
605000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1137000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
785000 usd
CY2023Q2 infi Accrued Development
AccruedDevelopment
855000 usd
CY2022Q4 infi Accrued Development
AccruedDevelopment
335000 usd
CY2023Q2 infi Accrued Consulting
AccruedConsulting
301000 usd
CY2022Q4 infi Accrued Consulting
AccruedConsulting
742000 usd
CY2023Q2 infi Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
45000 usd
CY2022Q4 infi Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
0 usd
CY2023Q2 infi Liability For Sale Of Future Royalties Current
LiabilityForSaleOfFutureRoyaltiesCurrent
1252000 usd
CY2022Q4 infi Liability For Sale Of Future Royalties Current
LiabilityForSaleOfFutureRoyaltiesCurrent
1218000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
633000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
593000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
401000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
655000 usd
CY2023Q2 infi Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
10562000 usd
CY2022Q4 infi Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
9223000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
700000 usd
CY2023Q2 infi Number Of Distinct Product Candidates
NumberOfDistinctProductCandidates
1 product
CY2023Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
4 position
CY2023Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.13
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
1708000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
842000 usd
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
821000 usd
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
45000 usd
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
1700000 usd

Files In Submission

Name View Source Status
0001113148-23-000009-index-headers.html Edgar Link pending
0001113148-23-000009-index.html Edgar Link pending
0001113148-23-000009.txt Edgar Link pending
0001113148-23-000009-xbrl.zip Edgar Link pending
ex-311q22023.htm Edgar Link pending
ex-321q22023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
infi-20230630.htm Edgar Link pending
infi-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
infi-20230630_cal.xml Edgar Link unprocessable
infi-20230630_def.xml Edgar Link unprocessable
infi-20230630_lab.xml Edgar Link unprocessable
infi-20230630_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
infi-20230630_pre.xml Edgar Link unprocessable